<DOC>
	<DOCNO>NCT00624767</DOCNO>
	<brief_summary>Insulin hormone produce human pancreas lower blood sugar . In patient n't produce enough insulin , additional insulin must give several time per day injection . Nastech Pharmaceutical Company Inc. develop new insulin nasal spray , possible way improve patient compliance intensive insulin treatment plan . This study conduct see Nastech 's insulin nasal spray affect post-meal glucose level compare rapid act insulin ( i.e. , insulin aspart ) Type 2 diabetic already take oral antidiabetic medication and/or insulin therapy . Insulin aspart market NovoLog® United States . The safety insulin nasal spray well tolerate compare NovoLog also evaluate .</brief_summary>
	<brief_title>A Study Evaluate Effect Nasal Insulin Postprandial Glycemic Control Type 2 Diabetic Patients</brief_title>
	<detailed_description>This study conduct evaluate effect postprandial glucose level safety Nastech 's insulin nasal spray compare rapid act insulin ( i.e. , insulin aspart ) Type 2 diabetic . Insulin aspart market NovoLog® United States NovoRapid® Europe . The target patient titration scheme 60 minute glucose read increase 3.3 mmol/L ( 60 mg/dL ) fast glucose level AND result hypoglycemia time within four hour post meal . NovoLog dose choose base patient 's current prandial insulin dose , dose 25 % basal insulin dose 8 IU oral antidiabetic therapy . Then patient titrate three additional consecutive treatment initial dose ( potential 4 dos NovoLog ) . Once patient reach target titrate dose NovoLog titrate nasal insulin . The nasal dose correspond injectable dose base bioavailability . For example , nasal formulation test study 17 % -28 % bioavailability compare NovoLog . Therefore 25 IU nasal dose correspond 4-7 IU NovoLog injectable dose . The patient titrate per dose nasal insulin three additional consecutive treatment initial dose ( potential 4 dos nasal insulin ) . Once patient successfully titrate NovoLog nasal insulin , randomize two-way crossover give NovoLog Nasal insulin . There least 20 hour washout period titration randomization stage . Patients monitor symptom consistent hypoglycemia . If need , treatment oral carbohydrate glucose tablet , fruit juice , non-diet soda provide . In event patient unable take oral glucose , intravenous 20 % glucose solution ( D20 ) available .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 2 diabetes least 3 month Type 2 diabetic oral antidiabetic medicine and/or insulin therapy Patients take intermediate acting insulin NPH Recurrent severe hypoglycemia Patients late diabetic complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>insulin</keyword>
	<keyword>insulin aspart</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>